Pembrolizumab for melanoma- safety profile and future trends

被引：7
作者：
Daud, Adil [1 ]
Nandoskar, Prachi [1 ]
机构：
[1] UCSF Helen Diller Comprehens Canc Ctr, Melanoma Clin Res, Dept Med Hematol Oncol, 1600 Divisadero St,Box 1297, San Francisco, CA 94115 USA
来源：
EXPERT OPINION ON DRUG SAFETY | 2016年 / 15卷 / 06期
关键词：
Melanoma; pembrolizumab; safety; cancer immunotherapy; PD-1; SOLID TUMORS; PATIENTS PTS; IPILIMUMAB; MK-3475; CHEMOTHERAPY; ASSOCIATION; KEYNOTE-002; THERAPY; CANCER; PEMBRO;
D O I：
10.1080/14740338.2016.1175430
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：727 / 729
页数：3
相关论文
共 50 条
[21]   Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis [J].
Zhang, Qi ;
Huo, Geng-wei ;
Zhang, Hong-zhen ;
Song, Ying .
OPEN MEDICINE, 2020, 15 (01) :447-456
[22]   Prognostic Value of Lactate Dehydrogenase in Patients with Melanoma Treated with Pembrolizumab [J].
Popovic, Aleksandar ;
Petkovic, Ivan ;
Dimitrijevic, Aleksandra ;
Jovic, Andrija .
ACTA DERMATOVENEROLOGICA CROATICA, 2023, 31 (02) :86-91
[23]   A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis [J].
Dagogo-Jack, Ibiayi ;
Lanfranchi, Michael ;
Gainor, Justin F. ;
Giobbie-Hurder, Anita ;
Lawrence, Donald P. ;
Shaw, Alice T. ;
Sullivan, Ryan J. .
JOURNAL OF IMMUNOTHERAPY, 2017, 40 (03) :108-113
[24]   Pembrolizumab use for the treatment of advanced melanoma [J].
Specenier, Pol .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) :765-780
[25]   Spotlight on pembrolizumab in the treatment of advanced melanoma [J].
Rajakulendran, Thanashan ;
Adam, David N. .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 :2883-2886
[26]   Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice [J].
Ksienski, Doran ;
Truong, Pauline T. ;
Croteau, Nicole S. ;
Chan, Angela ;
Sonke, Eric ;
Patterson, Tiffany ;
Clarkson, Melissa ;
Lesperance, Mary .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
[27]   Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma [J].
Hersey, Peter ;
Gowrishankar, Kavitha .
FUTURE ONCOLOGY, 2015, 11 (01) :133-140
[28]   Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma [J].
Faghfuri, Elnaz ;
Faramarzi, Mohammad Ali ;
Nikfar, Shekoufeh ;
Abdollahi, Mohammad .
EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (09) :981-993
[29]   Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis [J].
Li, Xin ;
Wang, Junpeng ;
Yao, Yun ;
Yang, Lei ;
Li, Zhiqin ;
Yu, Cheng ;
Zhao, Peiyan ;
Yu, Yongli ;
Wang, Liying .
ONCOTARGET, 2017, 8 (48) :83637-83649
[30]   Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions [J].
Karim, Safiya ;
Leighl, Natasha .
FUTURE ONCOLOGY, 2016, 12 (01) :9-23
12345